3026-69-5Relevant academic research and scientific papers
Stepwise aggregation of dimethyl-di-n-octylammonium chloride in aqueous solutions: From dimers to vesicles
Leclercq, Loic,Nardello-Rataj, Veronique,Turmine, Mireille,Azaroual, Nathalie,Aubry, Jean-Marie
, p. 1716 - 1723 (2010)
The self-aggregation of dimethyl-di-n-octylammonium chloride, in diluted aqueous solutions, was studied with various experimental and theoretical techniques: zetametry, conductimetry, dimethyl-di-n-octylammonium and chloride-selective electrodes, tensiometry, NMR spectroscopy (1H and DOSY), and molecular modeling (PM3 and molecular dynamic), The combination, of the data obtained by these techniques led us to propose a stepwise aggregation process with increasing concentration: dimers (0.2-10 mM), bilayers (10-30 mM), and finally vesicles (>30mM).
Acidic three-liquid-phase microemulsion systems based on balanced catalytic surfactant for epoxidation and sulfide oxidation under mild conditions
Fressancourt-Collinet, Marion,Hong, Bing,Leclercq, Loic,Alsters, Paul L.,Aubry, Jean-Marie,Nardello-Rataj, Veronique
supporting information, p. 409 - 420 (2013/05/22)
Didecyldimethylammonium tungstate has been designed as a balanced catalytic surfactant to form acidic three-liquid-phase microemulsion systems at room temperature in the presence of water, a non-chlorinated solvent and dimethyldioctylammonium salts (hydrogen sulfate and dihydrogen phosphate). The triphasic system is efficient for the oxidation of olefins, sulfides and thiophenes under mild conditions. Moreover, the recovery and reusability of the catalyst, the straightforward separation of products and catalysts in two distinct phases as well as the possible use of environmentally friendly solvents such as tert-butyl acetate, make this system particularly attractive for catalytic oxidation reactions involving hydrogen peroxide as the primary oxidant under acidic or neutral conditions.
Method of treating arrhythmia
-
, (2008/06/13)
A method of treating re-entrant arrhythmias comprising administering an effective dose of tetra-alkyl quaternary ammonium salt is provided. Pharmaceutical formulations containing a tetra-alkyl quaternary ammonium salt as the active ingredient are disclosed.
